First Personal Financial Services Raised Its Icici Bk LTD (IBN) Position; Shorts at Ocular Therapeutix (OCUL) Raised By 0.21%

Ocular Therapeutix Incorporated (NASDAQ:OCUL) had an increase of 0.21% in short interest. OCUL’s SI was 6.29M shares in May as released by FINRA. Its up 0.21% from 6.28M shares previously. With 945,800 avg volume, 7 days are for Ocular Therapeutix Incorporated (NASDAQ:OCUL)’s short sellers to cover OCUL’s short positions. The SI to Ocular Therapeutix Incorporated’s float is 32%. About 104,700 shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has risen 31.69% since September 27, 2016 and is uptrending. It has outperformed by 21.13% the S&P500.

First Personal Financial Services increased Icici Bk Ltd (IBN) stake by 4790.97% reported in 2016Q4 SEC filing. First Personal Financial Services acquired 274,331 shares as Icici Bk Ltd (IBN)’s stock declined 1.45%. The First Personal Financial Services holds 280,057 shares with $2.10M value, up from 5,726 last quarter. Icici Bk Ltd now has $26.89B valuation. The stock rose 4.01% or $0.35 reaching $9.2 per share. About 7.26M shares traded or 10.33% up from the average. ICICI Bank Ltd (ADR) (NYSE:IBN) has risen 13.32% since September 27, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.

Among 5 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix had 9 analyst reports since August 5, 2015 according to SRatingsIntel. On Wednesday, August 5 the stock rating was initiated by Nomura with “Buy”. The rating was initiated by JMP Securities with “Outperform” on Thursday, August 11. Morgan Stanley maintained the stock with “Overweight” rating in Thursday, April 28 report. The rating was maintained by Morgan Stanley on Tuesday, June 7 with “Overweight”. The company was initiated on Thursday, August 13 by Morgan Stanley. Morgan Stanley upgraded the shares of OCUL in report on Thursday, February 18 to “Overweight” rating. Cantor Fitzgerald initiated Ocular Therapeutix Inc (NASDAQ:OCUL) on Friday, February 10 with “Overweight” rating. The company was maintained on Tuesday, November 15 by RBC Capital Markets. Morgan Stanley downgraded the shares of OCUL in report on Friday, October 23 to “Equal-Weight” rating.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The company has market cap of $269.73 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It currently has negative earnings. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Among 5 analysts covering ICICI Bank (NYSE:IBN), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ICICI Bank had 9 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of ICICI Bank Ltd (ADR) (NYSE:IBN) earned “Buy” rating by Goldman Sachs on Monday, October 24. The stock has “Sell” rating by Zacks on Tuesday, August 25. Goldman Sachs upgraded the shares of IBN in report on Monday, September 14 to “Buy” rating. Standpoint Research upgraded ICICI Bank Ltd (ADR) (NYSE:IBN) rating on Wednesday, August 26. Standpoint Research has “Hold” rating and $12.0 target. The firm has “Hold” rating by Zacks given on Thursday, September 3. Credit Suisse upgraded ICICI Bank Ltd (ADR) (NYSE:IBN) on Thursday, April 21 to “Outperform” rating. As per Wednesday, August 19, the company rating was upgraded by Zacks. The rating was downgraded by Goldman Sachs on Tuesday, May 3 to “Neutral”. UBS upgraded ICICI Bank Ltd (ADR) (NYSE:IBN) on Friday, October 21 to “Buy” rating.